Complement activation in astrocytomas: deposition of C4d and patient outcome

BMC Cancer

Katri Mäkelä²  Pauli Helén¹  Hannu Haapasalo³  Timo Paavonen³ 

[1] Unit of Neurosurgery, Tampere University Hospital, Tampere, Finland

[2] University of Tampere, School of Medicine, Biokatu 6, Tampere 33520, Finland

[3] Department of Pathology, Fimlab laboratories, Tampere University Hospital, Tampere, Finland

关键词: Immunohistochemistry;    Survival;    Inflammation;    Complement;    C4d;    Glioblastoma;    Astrocytoma;   

Others  :  1080046
DOI  :  10.1186/1471-2407-12-565

 received in 2012-03-18, accepted in 2012-11-28,  发布年份 2012

【 摘 要 】

Background

C4d is a cleavage product of complement component C4 and is considered to serve as a marker for the site of complement activation. In this study C4d staining of grade I-IV astrocytic tumors was studied to explore if there is an association between complement activation and the grade of tumor, or patient survival.

Methods

Tissue micro-array samples of 102 astrocytomas were stained immunohistochemically. The material consisted of 9 pilocytic astrocytomas and 93 grade II-IV astrocytomas, of which 67 were primary resections and 26 recurrent tumors. The intensity of C4d staining as well as extent of C4d and CD34 staining were evaluated. The intensity of C4d staining was scored semiquantitatively. The extent of the staining was counted morphometrically with a point counting grid yielding a percent of C4d and CD34 positive area of the sample.

Results

The intensity and extent of C4d staining increased in grade II-IV diffusely infiltrating astrocytoma tumors in line with the malignancy grade (p = 0.034 and p = 0.016, respectively, Kruskal-Wallis test). However, C4d positive tumor area percentages were higher in grade I pilocytic astrocytomas than in grade II-IV diffusely infiltrating astrocytomas (p = 0.041, Mann–Whitney test). There was a significant correlation between CD34 positive and C4d positive endothelial area fraction in diffusely infiltrating astrocytomas (p < 0.001, Pearson correlation). In these tumors, the increasing intensity of C4d staining was also associated with worsened patient outcome (p = 0.014, log-rank test).

Conclusion

The worsening of patient outcome and malignant progression of tumor cells seem to be connected to microenvironmental changes evoked by chronically activated complement.

【 授权许可】

   
2012 Mäkelä et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Cavenee WK, Louis DN, Ohgaki H, Wiestler OD: World health organization classification of tumours of the central nervous system. France, Lyon; 2007.
• [2]Trouw LA, Daha MR: Role of complement in innate immunity and host defense. Immunol Lett 2011, 138:35-37.
• [3]Baldwin WM III, Kasper EK, Zachary AA, Wasowska BA, Rodriguez ER: Beyond C4d: other complement-related diagnostic approaches to antibody-mediated rejection. Am J Transplant 2004, 4:311-318.
• [4]Feucht H: Complement C4d in graft capillaries – the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003, 3:646-652.
• [5]Murata K, Baldwin WM III: Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) 2009, 23:139-150.
• [6]Lucas SD, Karlsson-Parra A, Nilsson B, Grimelius L, Akerström G, Rastad J, Juhlin C: Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 1996, 27:1329-1335.
• [7]Bu X, Zheng Z, Wang C, Yu Y: Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells. Pathol Res Pract 2007, 203:163-167.
• [8]Yin W, Ghebrehiwet B, Weksler B, Peerschke EI: Classical pathway complement activation on human endothelial cells. Mol Immunol 2007, 44:2228-2234.
• [9]Siitonen S, Haapasalo H, Rantala I, Helin H, Isola J: Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognosis value in a group of 77 selected node-negative breast carcinomas. Mod Pathol 1995, 8:745-752.
• [10]Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A, Voulgari P, Polyzoidis K, Kyritsis AP: Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol 2010, 226:136-142.
• [11]Shinoura N, Heffelfinger SC, Miller M, Shamraj OI, Miura NH, Larson JJ, DeTribolet N, Warnick RE, Tew JJ, Menon AG: RNA expression of complement regulatory proteins in human brain tumors. Cancer Lett 1994, 86:143-149.
• [12]Murray KP, Mathure S, Kaul R, Khan S, Carson LF, Twiggs LB, Martens MG, Kaul A: Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 2000, 76:176-182.
• [13]Mäenpää A, Junnikkala S, Hakulinen J, Timonen T, Meri S: Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 1996, 148:1139-1152.
• [14]Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S: Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000, 164:6075-6081.
• [15]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
• [16]Walport MJ: Complement. Second of two parts. N Engl J Med 2001, 344:1140-1144.
• [17]Hussain SP, Harris C: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007, 121:2373-2380.
• [18]Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140:883-899.